Clin2
NCT07369076Possibly a fitRecruiting

Testing NB-4746 for people with ALS

Amyotrophic Lateral Sclerosis (ALS)

Part of Brain & nervous system, Hormones & metabolism clinical trials.

This study tests an investigational drug called NB-4746 for people with ALS. The goal is to see if it can slow the progression of the disease. It is for people diagnosed within the last couple of years who are still able to eat and breathe on their own.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
80 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You are between 18 and 80 years old.
  • You have a confirmed diagnosis of ALS (Lou Gehrig's disease).
  • Your first ALS symptoms started less than 2 years ago (for Phase 2) or less than 4 years ago (for Phase 1).
  • You can eat and drink by mouth without a feeding tube.
  • You have a breathing test showing your lung function is at least 60% of normal.
  • You are not using a ventilator or breathing machine most of the day.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06351592Recruiting· Phase 1/Phase 2
Study of ALN-SOD for ALS with SOD1 gene mutation

This trial tests an experimental drug called ALN-SOD for people with ALS caused by a specific genetic mutation in the SOD1 gene. The goal is to see if it is safe and can help slow the disease.

Concord, New South Wales
NCT07138014Not yet recruiting· Phase 2
Investigational drug for amyotrophic lateral sclerosis

This study tests an investigational drug (FHND1002) for people with ALS to see if it can slow down the disease. It's for people with ALS who are in the early to moderate stages, have good breathing, and have been recently diagnosed.

NCT07833618Not yet recruiting· Phase 2
Study of ALT001 for people with ALS

This study tests an investigational drug called ALT001 in people with amyotrophic lateral sclerosis (ALS), a disease that affects nerve cells controlling muscles. The goal is to see if ALT001 can help slow the progression of the disease. Participants will receive the drug and be monitored for safety and effects.

Beijing, Beijing Municipality
NCT07589764Not yet recruiting· Phase 1
Testing a muscle supplement to lower a blood marker in ALS

This pilot study tests whether a muscle-supporting supplement called HMB can lower a blood marker (IGFBP7) that may be related to ALS. The goal is to see if this supplement is safe and could be a helpful addition to usual care for people with ALS.

Durham, North Carolina
NCT06126315Recruiting· Phase 2/Phase 3
Testing acetyl-L-carnitine in early ALS

This study tests a supplement called acetyl-L-carnitine (ALCAR) to see if it can slow the progression of ALS. It is for people in the early stages of the disease who are already taking riluzole and have good lung and muscle function.

Sydney
NCT07082192Recruiting· Phase 2/Phase 3
Testing CB03-154 for adults with ALS

This trial tests a new medicine, CB03-154, to see if it can help people with ALS. Researchers are comparing different doses to find the safest and most effective one.

Beijing, Beijing Municipality

Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.